CGC
Price
$1.31
Change
-$0.04 (-2.96%)
Updated
Oct 17 closing price
Capitalization
410.88M
20 days until earnings call
NBIX
Price
$140.09
Change
+$2.57 (+1.87%)
Updated
Oct 17 closing price
Capitalization
13.89B
10 days until earnings call
Interact to see
Advertisement

CGC vs NBIX

Header iconCGC vs NBIX Comparison
Open Charts CGC vs NBIXBanner chart's image
Canopy Growth
Price$1.31
Change-$0.04 (-2.96%)
Volume$23.35M
Capitalization410.88M
Neurocrine Biosciences
Price$140.09
Change+$2.57 (+1.87%)
Volume$977.24K
Capitalization13.89B
CGC vs NBIX Comparison Chart in %
CGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGC vs. NBIX commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGC is a Hold and NBIX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (CGC: $1.31 vs. NBIX: $140.09)
Brand notoriety: CGC: Notable vs. NBIX: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CGC: 90% vs. NBIX: 121%
Market capitalization -- CGC: $410.88M vs. NBIX: $13.89B
CGC [@Pharmaceuticals: Generic] is valued at $410.88M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $13.89B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGC’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 1 green FA rating(s).

  • CGC’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than CGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGC’s TA Score shows that 2 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).

  • CGC’s TA Score: 2 bullish, 6 bearish.
  • NBIX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than CGC.

Price Growth

CGC (@Pharmaceuticals: Generic) experienced а -4.38% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +2.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

CGC is expected to report earnings on Nov 07, 2025.

NBIX is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.9B) has a higher market cap than CGC($411M). NBIX YTD gains are higher at: 2.630 vs. CGC (-52.190). NBIX has higher annual earnings (EBITDA): 557M vs. CGC (-410.31M). NBIX has more cash in the bank: 976M vs. CGC (144M). CGC has less debt than NBIX: CGC (328M) vs NBIX (439M). NBIX has higher revenues than CGC: NBIX (2.51B) vs CGC (275M).
CGCNBIXCGC / NBIX
Capitalization411M13.9B3%
EBITDA-410.31M557M-74%
Gain YTD-52.1902.630-1,984%
P/E RatioN/A41.45-
Revenue275M2.51B11%
Total Cash144M976M15%
Total Debt328M439M75%
FUNDAMENTALS RATINGS
CGC vs NBIX: Fundamental Ratings
CGC
NBIX
OUTLOOK RATING
1..100
1670
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
10060
SMR RATING
1..100
9959
PRICE GROWTH RATING
1..100
6049
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
4n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (74) in the Biotechnology industry is in the same range as CGC (92) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to CGC’s over the last 12 months.

NBIX's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for CGC (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

NBIX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for CGC (99) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than CGC’s over the last 12 months.

NBIX's Price Growth Rating (49) in the Biotechnology industry is in the same range as CGC (60) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to CGC’s over the last 12 months.

NBIX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for CGC (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew significantly faster than CGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGCNBIX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 13 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 9 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
CGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HQIAX21.730.13
+0.60%
Hartford Equity Income A
WFILX59.020.31
+0.53%
Allspring Index A
MSBVX11.48N/A
N/A
Morgan Stanley American Resilience I
ASQGX17.40-0.04
-0.23%
American Century Small Company R5
AIVOX11.32-0.05
-0.44%
American Century International Opps A

CGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGC has been closely correlated with SNDL. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if CGC jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGC
1D Price
Change %
CGC100%
-2.96%
SNDL - CGC
77%
Closely correlated
-2.10%
ACB - CGC
67%
Closely correlated
-0.95%
TLRY - CGC
63%
Loosely correlated
+1.30%
OGI - CGC
62%
Loosely correlated
-3.70%
CRON - CGC
60%
Loosely correlated
+0.40%
More

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and ELAN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.87%
ELAN - NBIX
33%
Poorly correlated
+4.39%
LFCR - NBIX
32%
Poorly correlated
-0.61%
CGC - NBIX
30%
Poorly correlated
-2.96%
AMRX - NBIX
30%
Poorly correlated
+0.51%
AQST - NBIX
29%
Poorly correlated
+1.00%
More